Fennec Pharmaceuticals Inc's stock has seen a slight decline this week despite positive sales growth.
Fennec Pharmaceuticals Inc (FRX.TO) is having a tough week on the TSX, with its stock price down 3.85% over the past week. The company recently reported significant increases in net product sales, yet the stock price hasn't reacted positively.
Advertisement
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$617.65M
52W high
$17.64
52W low
$7.59
1W change
+10.95%
Beta
1.07
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 466.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+466.7% Upside
Current Price
C$16.51
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
63.0%
Annualized
90-Day Vol
80.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$19.74
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$17.52 | C$14.10 – C$21.78 |
| 60 trading days | C$18.60 | C$13.67 – C$25.29 |
| 90 trading days | C$19.74 | C$13.54 – C$28.77 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: While Fennec Pharmaceuticals has shown impressive sales growth in its recent financial reports, the stock's performance has been lackluster this week. Investors may want to keep an eye on further developments, especially regarding the company's financial health and market position.
Fennec Pharmaceuticals Reports 75% Increase in Q4 Sales
The company achieved net product sales of $13.8 million in Q4 2025, contributing to a full-year total of approximately $44.6 million.
Bull case
Fennec Pharmaceuticals has reported substantial growth in net product sales, with a 75% increase in the fourth quarter and a 50% increase for the full fiscal year. This positions the company well within the health care sector, especially as it continues to innovate and expand its product offerings.
Bear case
Despite the strong sales figures, Fennec Pharmaceuticals is facing challenges with a negative profit margin and a decline in stock price this week. Investors should remain cautious as the company navigates its financial landscape and market perceptions.
Price Action Overview
Advertisement
Fennec Pharmaceuticals Inc (FRX.TO) closed at C$14.22, showing no change in the stock price today. Over the past week, the stock has declined by 3.85%. However, year-to-date, it has increased by 36.60%, demonstrating strong long-term performance.
Recent Company Developments
While there have been no major announcements this week, Fennec Pharmaceuticals has previously reported impressive financial results. In March 2026, the company highlighted a 75% increase in Q4 2025 net product sales, reaching $13.8 million. This growth is notable and reflects the company's ongoing success in the health care sector.
Technical Picture
Fennec Pharmaceuticals is currently trading above its 50-day moving average of C$13.40, which is up 6.1% compared to its current price. The stock is also well above its 200-day moving average of C$11.35, reflecting a 25.3% increase. The 52-week range for the stock is between C$7.59 and C$15.48, indicating that it has traded at 84% of its range over the past year. With a beta of 1.07, the stock has shown slightly higher volatility compared to the market.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
